Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister
April 3, 2020
- PMDA Introduces 3 New Consultation Services
April 2, 2020
- PMDA Issues Q&A for Trial Implementations in Coronavirus Crisis
April 2, 2020
- Keidanren Calls for Review of Health Coverage for OTC-Like Drugs
April 2, 2020
- Japan’s Healthcare Would Collapse before “Overshoot,” Govt Panel Warns
April 2, 2020
- Japan Ruling Parties Call for Fund to Support Healthcare Delivery System
April 2, 2020
- MHLW Orders Label Revisions for Keytruda, Xofluza and More; 1st MID-NET-Based Safety Step Taken
April 1, 2020
- LDP to Suspend Committee Meetings from April 2-12
April 1, 2020
- Govt, LDP Moving to Review Supply Chains in Response to COVID-19 Pandemic
April 1, 2020
- Japan’s 1st In Vitro Diagnostic Test Kit for Novel Coronavirus Approved: Sysmex
March 31, 2020
- Global Health Confab Issues Proposals for Regulatory Harmonization in Asia
March 31, 2020
- Japan Hammers Out New 5-Year Health, Medical Strategy
March 30, 2020
- New Stable Supply Panel Wants to Define “Key Drugs” by This Summer
March 30, 2020
- PMDA Asking Companies to Seek Advice for Trial Rescheduling
March 30, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Ex-Tokyo Tech President Yoshinao Mishima Named AMED Chief from April
March 30, 2020
- Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate
March 27, 2020
- ICH Vancouver Meeting Cancelled due to COVID-19 Pandemic
March 27, 2020
- MHLW to Make Pediatric Medical Database Available to Researchers on Trial Basis
March 26, 2020
- OxyContin’s Chronic Pain Nod Delayed as Distribution System Not Ready
March 26, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…